Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.
Actively Recruiting
Researchers are evaluating a new treatment called MK-8748 for people with diabetic macular edema DME, a condition that can cause vision loss in people with diabetes. This trial compares MK-8748 to an existing standard treatment called aflibercept to see if MK-8748 works as well. The study is a randomized, double-masked, pivotal phase 3 trial focusing on treatment safety and effectiveness. Participants are assigned to one of three groups a low dose of MK-8748, a high dose of MK-8748, or the standard aflibercept treatment. Those receiving MK-8748 will get five initial injections every 4 weeks, then continue every 8 weeks until week 48, followed by personalized treatment intervals up to week 100. Participants in the aflibercept group receive injections every 4 weeks for five doses, then every 8 weeks up to week 100. During the study, participants will have regular eye exams and vision tests to measure changes in visual acuity and eye thickness. Researchers will monitor how well treatments reduce retinal swelling and improve diabetic retinopathy severity using imaging and questionnaires. Safety will be closely observed, including adverse events and antibody levels, over approximately two years. The main focus is to assess the change in best-corrected visual acuity from baseline to one year.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of JNJ-81201887, given as an injection into the eye, for people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This extension study follows participants who took part in earlier parent studies to continue monitoring their health without new treatments given during this phase. The study aims to understand how participants respond over an extended period after the initial treatment. Participants who previously received either a low or high dose of JNJ-81201887, or a sham procedure, in earlier clinical trials will join this long-term extension study. No additional treatments or interventions will be provided during this study. The trial is designed to observe participants without administering further study drugs, focusing on those who were part of the parent studies identified by specific study codes. Throughout the study, participants will be monitored for up to 5 years. Assessments will include checking for any eye-related or systemic side effects, abnormalities in laboratory tests, retinal imaging, and eye examinations. Visual acuity changes will also be measured from baseline up to 42 months. Participants will provide informed consent and be regularly evaluated to track their health and visual function over time.
Actively Recruiting
Researchers are investigating the effects of APL-3007 combined with SyfovrePegcetacoplan APL-2 in patients with geographic atrophy caused by age-related macular degeneration AMD. This Phase 2 randomized, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacodynamics of these treatments in this eye condition. The study involves multiple centers and uses a masked design to ensure unbiased results. Participants will be assigned to one of three groups two receiving different doses or frequencies of APL-3007 in combination with pegcetacoplan APL-2, and one receiving a placebo along with pegcetacoplan APL-2. The study will evaluate the treatments given as multidose regimens. The treatments focus on complement C3 inhibition to potentially impact disease progression. Throughout the study, participants will undergo assessments including artificial intelligence-based imaging to measure retinal pigment epithelium lesion area and photoreceptor degeneration, safety evaluations through adverse event reporting and visual acuity tests, and blood tests to assess serum markers. These evaluations occur over 12 months to monitor changes from baseline. Participants involvement includes regular visits for these assessments, with the study tracking treatment effects and safety over the duration.
Actively Recruiting
Researchers are evaluating the similarity in effectiveness between ABP 938 8 mg and Aflibercept US 8 mg in people with neovascular age-related macular degeneration nAMD. The study aims to compare changes in best corrected visual acuity BCVA to understand how these treatments perform in improving vision for participants with this eye condition. Participants will be randomly assigned to receive intravitreal injections of either ABP 938 8 mg or Aflibercept 8 mg at the start of the study, Week 4, and Week 8. After these initial doses, participants will be regularly assessed starting at Week 16 to adjust injection schedules based on disease activity. The injections may then continue at intervals ranging from every 4 to 16 weeks up until the end of the study. Throughout the trial, participants will attend scheduled visits where vision tests like BCVA and imaging scans such as spectral-domain optical coherence tomography SD-OCT and fluorescein angiography FA will be performed. Researchers will monitor changes in vision, retinal fluid presence, lesion size, and safety outcomes including adverse events and immune responses. The study includes ongoing assessments of drug levels in blood samples, with participation lasting through multiple weeks with continuous monitoring.
Actively Recruiting
Researchers are studying the safety and effectiveness of tabirafusp tedromer compared to aflibercept in people with diabetic macular edema DME, a condition causing vision impairment related to diabetes. This phase 3 randomized trial aims to evaluate these two treatments administered by injection into the eye, focusing on improving vision clarity. Participants receive intravitreal injections of either tabirafusp tedromer or aflibercept. Tabirafusp tedromer is given once every 4 weeks for six doses, then either every 8 weeks or individualized between every 4 to 24 weeks depending on the group. Aflibercept is administered every 4 weeks for five doses, followed by every 8 weeks. The study compares these dosing schedules over time to assess treatment impact. During the trial, participants undergo regular eye exams to measure best corrected visual acuity at week 52 and other safety assessments. The study includes monitoring of treatment effects and side effects through scheduled visits with injections and vision tests. Participation lasts through the treatment and evaluation period, allowing researchers to gather data on vision changes and overall safety.
Actively Recruiting
Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.
Actively Recruiting
Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.
Actively Recruiting
Researchers are studying colorectal cancer incidence in people aged 45 to 70 who have 1 to 2 small, non-advanced adenomas found on colonoscopy. The trial compares two surveillance strategies performing follow-up colonoscopies at both 5 and 10 years versus only at 10 years. The goal is to better understand the timing and benefit of surveillance colonoscopy for this common condition, as current guidelines vary and lack strong randomized evidence. Participants are randomly assigned to receive either a surveillance colonoscopy at 5 and 10 years or at 10 years only after their qualifying colonoscopy. The colonoscopies will follow current quality guidelines, with all polyps completely removed during the initial exam. Standard preparation instructions will be given before each colonoscopy. This study aims to provide clear evidence on the best interval for surveillance after detecting non-advanced adenomas. During the study, participants will be monitored for colorectal cancer development over 10 years, which is the primary outcome measure. Follow-up includes scheduled colonoscopies and any necessary unscheduled procedures according to clinical need. The study will collect data on cancer incidence to guide future clinical recommendations. Participants will be followed until the study ends with safety and health closely observed throughout their participation.
Actively Recruiting
Researchers are evaluating whether 6 months of HER2-targeted therapy is as effective as 12 months for treating early-stage HER2-positive breast cancer in patients who have no remaining invasive cancer after preoperative chemotherapy with trastuzumab. The study aims to compare recurrence-free survival and quality of life between shorter and longer treatment durations. Secondary goals include assessing serious side effects, overall survival, local cancer recurrence, and patient-reported symptoms. Participants are randomly assigned to either 6 months or 12 months of HER2-targeted therapy using trastuzumab and possibly pertuzumab, given intravenously or subcutaneously every 21 days. Treatment continues up to 9 or 17 cycles unless disease progresses or side effects are unacceptable. During the trial, participants undergo heart function tests ECHO or MUGA, imaging such as mammography, ultrasound, or MRI, and may provide blood and tissue samples for research. After treatment, participants are followed every 6 months for 5 years or until cancer recurrence, then annually up to 10 years. Researchers monitor recurrence-free survival and quality of life using validated questionnaires. Safety is closely tracked through adverse event reporting, and long-term outcomes including overall survival and brain metastasis occurrence are assessed to understand treatment impact.